Your session is about to expire
← Back to Search
APG-2575 for Blood Cancers
Study Summary
This trial is testing a new cancer drug, APG-2575, to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there opportunities for individuals to participate in this research?
"Affirmative. Clinicaltrials.gov reveals that this trial, created on August 7th 2018, is recruiting participants as of today. 90 individuals need to be enrolled across 4 sites."
How many individuals are being enrolled in this examination?
"To commence the trial, 90 qualifying individuals are needed. Ascentage Pharma Group Inc., is responsible for operating said study; and it will occur across multiple sites such as Duke University in Jacksonville and MDACC in Durham, North carolina."
Could you provide a count of the centers hosting this experiment in town?
"Currently, 4 sites are accepting patient enrolment. These locations sit in Jacksonville, Durham and Houston with additional locations located nearby to minimise travel for those who join the trial."
Share this study with friends
Copy Link
Messenger